CTOs on the Move

ExonHit Therapeutics

www.exonhit.com

 
ExonHit Therapeutics is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.exonhit.com
  • 217 Perry Pkwy Ste 5
    Gaithersburg, MD USA 20877
  • Phone: 240.683.7070

Executives

Name Title Contact Details

Similar Companies

Ratiopharm Inc

Ratiopharm Inc is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cebert Pharmaceuticals

Cebert Pharmaceuticals is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centessa

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with a Research & Development innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development. We are headquartered in Boston, Massachusetts.

Phagetech

Phagetech is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.